Form 4: Amarin Corp Chief Scientific Officer Granted Stock Options

Amarin Corp's Chief Scientific Officer, Steven B. Ketchum, was granted stock options for 663,878 ordinary shares on January 10, 2025.

Summary

• Steven B. Ketchum, Chief Scientific Officer of Amarin Corp, was granted stock options to purchase 663,878 ordinary shares.
• The grant occurred on January 10, 2025, with an exercise price of $0.62 per share.
• The options vest over 18 months, with 50% vesting on the first anniversary of the grant date and the remaining 50% vesting six months later.
• The options expire on January 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with the company's long-term success.
• The vesting schedule encourages the officer's continued service and contribution to the company over the next 18 months.

Future Outlook

The stock options will vest over the next 18 months, incentivizing the Chief Scientific Officer to contribute to the company's success.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the pharmaceutical industry, similar to companies like Regeneron, Biogen, and Gilead Sciences.
• The vesting schedule of 18 months is also typical, aligning with industry norms for executive retention and performance incentives.

Stakeholder Impact

• The stock option grant aligns the Chief Scientific Officer's interests with those of shareholders, potentially leading to increased value.
• The vesting schedule encourages the officer's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, Amarin Corp, AMRN, Chief Scientific Officer, Steven B. Ketchum, equity